Download in electronic PDF format for $25

Kalchem International - Chemicals and Compounding Supplies

Search the Complete Journal Archives

PreScription: Compounding Pharmacy Issues for 2017

Author(s):  Allen Loyd V Jr

Issue:  Jan/Feb 2017 - Volume 21, Number 1
View All Articles in Issue

Abstract:  

Related Keywords: Loyd V. Allen, Jr., PhD, RPh, U.S. Food and Drug Administration, FDA, Drug Quality and Security Act, DQSA, regulation, regulatory policy, state boards of pharmacy, pharmacy inspectors, pharmacy inspection, pharmaceutical benefit managers, PBM, pharmacy education, pharmacy technicians, regulatory overreach

Related Categories: BUSINESS, LEGAL, PHARMACY EDUCATION, PROFESSIONAL ISSUES

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr Jul/Aug 2016 351 View Sample
PreScription: Compounding Pharmacy Issues for 2017 Allen Loyd V Jr Jan/Feb 2017 4 Buy
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug Mar/Apr 2017 95-102 Buy
Standing Together Fixing the Drug Quality and Security Act Miller David G Mar/Apr 2015 104-106 Buy
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr Sep/Oct 2017 356 Buy
Applying Quality of Design Concepts to Pharmacy Compounding Timko Robert J Nov/Dec 2015 453-463 Buy
PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing Allen Loyd V Jr Mar/Apr 2018 92 Buy
Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies Pritchett Jon, McCrory Gary, Kraemer Cheri, Jensen Brenda, Allen Loyd V Jr Jan/Feb 2018 7-16 Buy
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr Sep/Oct 2015 389-390 Buy
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr Nov/Dec 2015 487-488 Buy